List view / Grid view
13 January 2016 | By Victoria White
IONIS-HBV-LRx (previously referred to as ISIS-GSK6-LRx) is a drug Ionis is developing with GSK for the treatment of patients with hepatitis B virus...
13 January 2016 | By Victoria White
The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, according to research and consulting firm GlobalData...
13 January 2016 | By Victoria White
Results from a study demonstrate that Roche’s cardiac troponin T-high-sensitivity test shortens the time to diagnose heart attack to one hour from three hours or more...
13 January 2016 | By Victoria White
GlobalData states that this impressive growth will be driven primarily by the launch of Bristol-Myers Squibb’s Orencia from 2021...
12 January 2016 | By Dolomite
A Dolomite microfluidic system is helping Dr Samar Damiati, Assistant Professor in the Biochemistry Department at King Abdulaziz University in Saudi Arabia, perform drug encapsulation studies...
12 January 2016 | By Shimadzu
Less solvent consumption, no cross contamination / Can be combined with Shimadzu’s GCMS-TQ8040 triple quadrupole / Both fulfill new EU 589/2014 regulation on analyzing dioxins and PCBs samples...
12 January 2016 | By Victoria White
The NDA for venetoclax is for the treatment of people with chronic lymphocytic leukaemia who have received at least one prior therapy, including those with 17p deletion...
DiscoveRx Corporation, the leading supplier of innovative cell-based assays and services for drug discovery and development, announces the expansion of its PathHunter® cell-based assays portfolio with the release of PathHunter Interleukin cell-based assays.
12 January 2016 | By Victoria White
ECCS-50 is an autologous, adipose-derived cell therapy produced at the patient’s bedside and administered via a series of hand injections, in a single same-day procedure...
12 January 2016 | By Victoria White
An analyst at GBI Research states that the pipeline for the disease is highly active, consisting of 365 programmes across all stages of development, and a diverse range of molecular targets...
12 January 2016 | By Victoria White
Nestlé Health Science has signed an exclusive agreement outside the US and Canada for Seres Therapeutics’ Ecobiotics in clostridium difficile infections and inflammatory bowel disease...
12 January 2016 | By Victoria White
Eisai has submitted the MAA to the EMA for the use of lenvatinib in combination with everolimus to treat people with unresectable advanced or metastatic renal cell carcinoma who have received one prior vascular endothelial growth factor targeted therapy...
11 January 2016 | By Victoria White
The company will first be evaluating foralumab in two clinical indications: graft vs host disease; and ulcerative colitis...
11 January 2016 | By Victoria White
The combination of Shire and Baxalta will create the number one rare diseases platform in revenue and pipeline depth...
11 January 2016 | By Victoria White
AbbVie's investigational HCV regimen, combining ABT-493 and ABT-530, will be evaluated in patients with genotypes 1-6 chronic HCV infection...
